Largest biotech companies in the United States by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Amgen leads the 17 biotech companies in the United States ranked by revenue, at SAR 137.9B, ahead of Gilead Sciences (SAR 110.5B) and Biogen (SAR 37.1B). Figures as of 20 Nov 2026, 23:52 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 17
- First
- AmgenSAR 137.9B
- Median
- SAR 2.8B
- Combined market value
- SAR 2.73T
- Countries
- 1
- Not ranked
- 3no revenue on file
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | SAR 137.9B | SAR 884B | SAR 1,634.30 | 0.15% down | 30% up | ||
| 2 | Gilead SciencesGILD · Health Care | SAR 110.5B | SAR 774.4B | SAR 624.36 | 0.06% down | 31% up | ||
| 3 | BiogenBIIB · Health Care | SAR 37.1B | SAR 138.4B | SAR 936.34 | 1.00% up | 41% up | ||
| 4 | Neurocrine BiosciencesNBIX · Health Care | SAR 10.7B | SAR 57.2B | SAR 564.86 | 3.84% down | 10% up | ||
| 5 | ExelixisEXEL · Health Care | SAR 8.7B | SAR 59.2B | SAR 242.46 | 1.82% down | 55% up | ||
| 6 | ModernaMRNA · Health Care | SAR 7.3B | SAR 296B | SAR 731.54 | 2.17% down | 740% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | SAR 5.2B | SAR 39.1B | SAR 342.70 | 1.82% down | 32% up | ||
| 8 | Bio-TechneTECH · Health Care | SAR 4.6B | SAR 42.8B | SAR 272.62 | 0.04% down | 18% up | ||
| 9 | RepligenRGEN · Health Care | SAR 2.8B | SAR 39.3B | SAR 614.53 | 3.81% down | 5% up | ||
| 10 | Krystal BiotechKRYS · Health Care | SAR 1.5B | SAR 34.3B | SAR 1,158.80 | 2.19% down | 49% up | ||
| 11 | Twist BioscienceTWST · Health Care | SAR 1.4B | SAR 26.4B | SAR 387.60 | 7.44% down | 291% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | SAR 1B | SAR 17B | SAR 104.78 | 0.43% down | 51% up | ||
| 13 | ImmunityBioIBRX · Health Care | SAR 425M | SAR 24B | SAR 22.58 | 8.37% down | 216% up | ||
| 14 | Kymera TherapeuticsKYMR · Health Care | SAR 147.1M | SAR 36.9B | SAR 432.59 | 3.42% down | 81% up | ||
| 15 | CG OncologyCGON · Health Care | SAR 15.2M | SAR 26.6B | SAR 298.13 | 2.97% down | 93% up | ||
| 16 | Revolution MedicinesRVMD · Health Care | SAR 0 | SAR 130.8B | SAR 604.74 | 1.11% up | 125% up | ||
| 17 | Scholar Rock HoldingSRRK · Health Care | SAR 0 | SAR 22B | SAR 180.56 | 4.45% down | 25% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7515 SAR). 3 companies have no revenue on file and are not ranked here.
Questions and answers
Which biotech companies in the United States rank first by revenue?
Amgen (SAR 137.9B), Gilead Sciences (SAR 110.5B) and Biogen (SAR 37.1B) are the top three of the 17 biotech companies in the United States ranked by revenue as of 20 Nov 2026, 23:52 UTC.
How many biotech companies in the United States are in this ranking?
17 are ranked by revenue. 3 more have no revenue on file and are left out rather than ranked at zero.
What are these biotech companies in the United States worth together?
The 17 biotech companies in the United States ranked by revenue have a combined market value of SAR 2.73T as of 20 Nov 2026, 23:52 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech companies in the United States by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.